Part three of our four-part spotlight on Australia. In this series of short articles, we profile Australia and three of its main cities for life sciences innovation: Melbourne, Brisbane, and Sydney.

Australia - Brisbane


Queensland, and its capital city Brisbane, are well known both in Australia and globally for their strengths in pre-farm gate technology, tropical health, and functional foods. Brisbane’s proximity to a large area of tropical cultivatable land lends itself to food and agribusiness companies, and its government support benefits biotech and health innovation through both policy and capital investment.

More than 80 biotechnology companies locate in Queensland. In early 2015, University of Queensland spin-off Vaxxas raised AUD25 million (USD18 million) for its novel needle-free vaccine technology, which is it commercialising with Merck for specific candidates. Anatara, a listed animal health company, is targeting the critical issue of antibiotic overuse and resistance, with the advantage of proximity to a number of pork producers.

Brisbane and the wider Queensland area are home to 47 biotechnology-related research institutes, 10 universities, and 12 teaching hospitals. Among the universities based here is the University of Queensland, ranked in the top 100 life science universities worldwide (Times Higher Education rankings).

Brisbane also possesses robust research infrastructure, including the Queensland Bioscience Precinct, the Translational Research Institute, and the Health and Food Sciences Precinct. These structures foster collaboration between universities, public research institutes, and industry.

BioPacific Partners in Brisbane

Two of BioPacific Partners’ Venture Partners, Mel Bridges and Peter Andrews, are Brisbane-based.

The industry here is supported by Life Sciences Queensland, an industry-led organisation that helps to direct events, advocacy, and sector growth. We are connected with this group and many of their members, as well as the national AusBiotech organisation.

BioPacific Partners has strong relationships with companies and institutes operating across Australia, providing our Partners with an extended network of their own. We specialise in bridging the best of innovation from this region into global markets so contact us if you think we can help you, or explore our Innovation Portfolio for real examples of our work.

By Emma Armitage and Joerg Kistler, BioPacific Partners

To read all articles in the Spotlight on Australian life sciences series, see the profiles for  Melbourne, Sydney and Adelaide.

About Emma Armitage

No Comments

Be the first to start a conversation

Leave a Reply

  • (will not be published)